News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Orexo AB Announces Successful Completion of the First Clinical Trial With OX27


6/14/2011 9:26:31 AM

UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo AB (STO:ORX) announces a successful outcome following completion of the first OX27 pharmacokinetic trial. OX27 is a sublingual tablet developed to optimize the treatment of breakthrough pain in cancer patients. The market for treatment of breakthrough pain in cancer patients is approximately 1.5 billion USD in Europe and United States.

Read at BioSpace.com


comments powered by Disqus
Orexo AB
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES